Logo image of TCRX

TSCAN THERAPEUTICS INC (TCRX) Stock Fundamental Analysis

NASDAQ:TCRX - Nasdaq - US89854M1018 - Common Stock

2.53  +0.16 (+6.75%)

Fundamental Rating

3

Taking everything into account, TCRX scores 3 out of 10 in our fundamental rating. TCRX was compared to 572 industry peers in the Biotechnology industry. While TCRX seems to be doing ok healthwise, there are quite some concerns on its profitability. TCRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TCRX has reported negative net income.
In the past year TCRX has reported a negative cash flow from operations.
In the past 5 years TCRX always reported negative net income.
TCRX had a negative operating cash flow in each of the past 5 years.
TCRX Yearly Net Income VS EBIT VS OCF VS FCFTCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of TCRX (-31.98%) is better than 65.31% of its industry peers.
TCRX's Return On Equity of -48.59% is fine compared to the rest of the industry. TCRX outperforms 66.73% of its industry peers.
Industry RankSector Rank
ROA -31.98%
ROE -48.59%
ROIC N/A
ROA(3y)-30.63%
ROA(5y)-34.42%
ROE(3y)-52%
ROE(5y)-68.01%
ROIC(3y)N/A
ROIC(5y)N/A
TCRX Yearly ROA, ROE, ROICTCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

TCRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCRX Yearly Profit, Operating, Gross MarginsTCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

More info and screens

4

2. Health

2.1 Basic Checks

TCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TCRX has more shares outstanding
The debt/assets ratio for TCRX has been reduced compared to a year ago.
TCRX Yearly Shares OutstandingTCRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M
TCRX Yearly Total Debt VS Total AssetsTCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -0.95, we must say that TCRX is in the distress zone and has some risk of bankruptcy.
TCRX has a Altman-Z score (-0.95) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.13 indicates that TCRX is not too dependend on debt financing.
TCRX has a Debt to Equity ratio of 0.13. This is in the lower half of the industry: TCRX underperforms 67.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -0.95
ROIC/WACCN/A
WACC11.48%
TCRX Yearly LT Debt VS Equity VS FCFTCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 9.56 indicates that TCRX has no problem at all paying its short term obligations.
TCRX has a better Current ratio (9.56) than 79.29% of its industry peers.
TCRX has a Quick Ratio of 9.56. This indicates that TCRX is financially healthy and has no problem in meeting its short term obligations.
TCRX has a Quick ratio of 9.56. This is in the better half of the industry: TCRX outperforms 79.47% of its industry peers.
Industry RankSector Rank
Current Ratio 9.56
Quick Ratio 9.56
TCRX Yearly Current Assets VS Current LiabilitesTCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

TCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.91%, which is quite impressive.
Looking at the last year, TCRX shows a very negative growth in Revenue. The Revenue has decreased by -44.73% in the last year.
TCRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 168.29% yearly.
EPS 1Y (TTM)56.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.17%
Revenue 1Y (TTM)-44.73%
Revenue growth 3Y168.29%
Revenue growth 5YN/A
Sales Q2Q%-73.01%

3.2 Future

Based on estimates for the next years, TCRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.30% on average per year.
The Revenue is expected to grow by 32.70% on average over the next years. This is a very strong growth
EPS Next Y39.8%
EPS Next 2Y16.91%
EPS Next 3Y8.26%
EPS Next 5Y8.3%
Revenue Next Year-79.39%
Revenue Next 2Y-53.46%
Revenue Next 3Y-22.08%
Revenue Next 5Y32.7%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TCRX Yearly Revenue VS EstimatesTCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
TCRX Yearly EPS VS EstimatesTCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TCRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCRX Price Earnings VS Forward Price EarningsTCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCRX Per share dataTCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.91%
EPS Next 3Y8.26%

More info and screens

0

5. Dividend

5.1 Amount

TCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TSCAN THERAPEUTICS INC

NASDAQ:TCRX (1/22/2025, 2:02:43 PM)

2.53

+0.16 (+6.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners99.35%
Inst Owner Change0.01%
Ins Owners0.34%
Ins Owner Change0.59%
Market Cap142.97M
Analysts84.29
Price Target12.39 (389.72%)
Short Float %4.88%
Short Ratio5.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.88%
Min EPS beat(2)2.95%
Max EPS beat(2)14.81%
EPS beat(4)3
Avg EPS beat(4)6.11%
Min EPS beat(4)-22.31%
Max EPS beat(4)29.01%
EPS beat(8)5
Avg EPS beat(8)9.45%
EPS beat(12)9
Avg EPS beat(12)13.35%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-40.66%
Min Revenue beat(2)-78.27%
Max Revenue beat(2)-3.05%
Revenue beat(4)1
Avg Revenue beat(4)-13.93%
Min Revenue beat(4)-86.04%
Max Revenue beat(4)111.65%
Revenue beat(8)2
Avg Revenue beat(8)-6.87%
Revenue beat(12)4
Avg Revenue beat(12)-2.61%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.41%
PT rev (3m)-3.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.5%
EPS NY rev (1m)0%
EPS NY rev (3m)5.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-44.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.27
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB 0.62
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-1.96
FCFYN/A
OCF(TTM)-1.9
OCFYN/A
SpS0.17
BVpS4.05
TBVpS4.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.98%
ROE -48.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.63%
ROA(5y)-34.42%
ROE(3y)-52%
ROE(5y)-68.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 72.74%
Cap/Sales 36.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.56
Quick Ratio 9.56
Altman-Z -0.95
F-Score3
WACC11.48%
ROIC/WACCN/A
Cap/Depr(3y)146.49%
Cap/Depr(5y)204.92%
Cap/Sales(3y)48.07%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.17%
EPS Next Y39.8%
EPS Next 2Y16.91%
EPS Next 3Y8.26%
EPS Next 5Y8.3%
Revenue 1Y (TTM)-44.73%
Revenue growth 3Y168.29%
Revenue growth 5YN/A
Sales Q2Q%-73.01%
Revenue Next Year-79.39%
Revenue Next 2Y-53.46%
Revenue Next 3Y-22.08%
Revenue Next 5Y32.7%
EBIT growth 1Y-31.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.49%
EBIT Next 3Y-17.26%
EBIT Next 5YN/A
FCF growth 1Y-58.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.22%
OCF growth 3YN/A
OCF growth 5YN/A